Elanco Animal Health Inc (N:ELAN)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 2500 Innovation Way N
GREENFIELD IN 46140-9163
Tel: N/A
Website: https://www.elanco.com
IR: See website
<
Key People
R. David Hoover
Independent Chairman of the Board
James M. Meer
Chief Accounting Officer
Jeffrey N. Simmons
President, Chief Executive Officer, Director
Todd S. Young
Chief Financial Officer, Executive Vice President
Michael-Bryant Hicks
Executive Vice President, General Counsel, Corporate Secretary
David S. Kinard
Executive Vice President of Human Resources
Sarena S. Lin
Executive Vice President - Elanco USA, Corporate Strategy and Global Marketing
Ramiro M. Cabral
Executive Vice President - Elanco International
Aaron L. Schacht
Executive Vice President - Innovation, Regulatory, Business Development
David A. Urbanek
Executive Vice President - Manufacturing, Quality
   
Business Overview
Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.
Financial Overview
For the fiscal year ended 31 December 2019, Elanco Animal Health Inc revenues remained flat at $3.07B. Net income decreased 22% to $67.9M. Revenues reflect market conditions. Net income was partially offset by Interest Exp-Net of Capitalized Interest increase from $29.6M to $78.9M (expense), Marketing, selling and administrative increase of 3% to $760.2M (expense), Research and development increase of 10% to $270.1M (expense).
Employees: 5,590 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $3,071M as of Dec 31, 2019
EBITDA (TTM): $684.40M as of Dec 31, 2019
Net annual income (TTM): $67.90M as of Dec 31, 2019
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 397,975,718 as of Jan 22, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization